183 related articles for article (PubMed ID: 22292376)
1. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
Li Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
[TBL] [Abstract][Full Text] [Related]
2. The Food and Drug Administration risk evaluation and mitigation strategy.
Craig DS
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
[TBL] [Abstract][Full Text] [Related]
3. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang].
He W; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395
[TBL] [Abstract][Full Text] [Related]
4. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
5. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
6. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
Yu X; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
[TBL] [Abstract][Full Text] [Related]
7. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
Zhou A; Lian F
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
[TBL] [Abstract][Full Text] [Related]
8. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
Wang X; Su X; Yu J; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
[TBL] [Abstract][Full Text] [Related]
9. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
Zhang W; Xie YM; Yu WY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
[TBL] [Abstract][Full Text] [Related]
10. Risk management of marketed drugs: FDA and the interface with the practice of medicine.
Uhl K; Honig P
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):205-8. PubMed ID: 11501332
[No Abstract] [Full Text] [Related]
11. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
Kou Q; Zhao S; Feng G; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
[TBL] [Abstract][Full Text] [Related]
12. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
14. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
15. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
16. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
Fu Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
[TBL] [Abstract][Full Text] [Related]
17. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
19. Has the FDA Amendments Act of 2007 impaired drug development?
Franson TR
Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
[TBL] [Abstract][Full Text] [Related]
20. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
Sloan PA
J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
